β-Blockers and Diuretics: To Use or Not to Use

American Journal of Hypertension

Volumn 12, Issue 12 II SUPPL., 1999, Pages

  Messerli, Franz H ^a   Grossman, Ehud ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b NONE

Author keywords

All cause mortality; Cardiovascular; Coronary heart disease; Diuretics; Prospective randomized trials; Renal cell carcinoma; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT;

DECISION MAKING; DRUG COMBINATION; FEMALE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MORTALITY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SURVIVAL RATE;

ADRENERGIC BETA-ANTAGONISTS; CARCINOMA, RENAL CELL; DECISION MAKING; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY NEOPLASMS; MALE; PRACTICE GUIDELINES; RISK FACTORS; SURVIVAL RATE;

EID: 0033255729     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00220-4     Document Type: Article

References (55)

1. Messerli FH, Grossman E: Diuretics, β-blockers, and gin and tonic. Eur Heart J 1999;20:25-30.
2. Messerli FH: Diuretic therapy and renal cell carcinoma - another controversy. Eur Heart J, 1999;20:1441- 1442.
3. Prichard BNC, Gillam PMS: Use of propranolol (Inderal) in treatment of hypertension. Br Med J 1964;2: 725-727.
4. Messerli FH, Grossman E, Goldbourt U: Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-1907.
5. Hoes AW, Grobbee DE, Lubsen J, Man in't Veld AJ, van der Does E, Hofman A: Diuretics, β-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995;123:482-487.
6. Psaty BM, Smith NL, Koepsell TD, Furberg CD: In reply (letter). JAMA 1997;277:1759-1760.
7. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-745.
8. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.
9. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester P-O: Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991;338:1281-1285.
10. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
11. Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986;293:1145-1151.
12. Grossman E, Messerli FH, Goldbourt U: Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999;83:1090-1093.
13. Hamet P: Cancer and hypertension. An unresolved issue. Hypertension 1996;28:321-324.
14. Loffing J, Loffing-Cueni D, Hegyi I, Kaplan MR, Hebert SC, Le Hir M, Kaissling B: Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int 1996;50:1180-1190.
15. Vogelzang NJ, Stadler WM: Kidney cancer. Lancet 1998; 352:1691-1696.
16. Klungel OH, de Boer A, Paes AH, Seidell JC, Bakker A: Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. J Hypertens 1998;16:1545-1553.
17. Verlander JW, Tran TM, Zhang L, Kaplan MR, Hebert SC: Estradiol enhances thiazide-sensitive NaCl cotransporter density in the apical plasma membrane of the distal convoluted tubule in ovariectomized rats. J Clin Invest 1998;101:1661-1669.
18. Messerli FH, Grossman E, Goldbourt U: Diuretic therapy and renal cell carcinoma - what is the true risk/benefit ratio? (abstract). Am J Hypertens 1999;12:137a.
19. Lee DVI, Hennekens CH: Diuretics and renal cell carcinoma (editorial). Am J Cardiol 1999;83:1094.
20. Messerli FH, Sundgaard-Riise K, Ventura HO, Dunn FG, Glade LB, Frohlich ED: Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983;2:983-986.
21. Lund-Johansen P, Omvik P: Hemodynamic patterns of untreated hypertensive disease, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. Vol. 1. 2nd ed. Raven Press, Ltd., New York, 1995, pp 323-342.
22. Lund-Johansen P: Hemodynamic consequences of long-term β-blocker therapy: a 5-year follow-up study of atenolol. J Cardiovasc Pharmacol 1979;1:487-495.
23. Man in't Veld AJ, Van Den Meiracker AH, Schalekamp MA: Do β-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens 1988;1: 91-96.
24. Cruickshank JM, Lewis J, Moore V, Dodd C: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6: 85-90.
25. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-1513.
26. Schulman SP, Weiss JL, Becker LC, Gottlieb SO, Woodruff KM, Weisfeldt ML, Gerstenblith G: The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990;322:1350-1356.
27. Neaton JD, Grim RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson PR for the Treatment of Mild Hypertension Study Research Group: Treatment of Mild Hypertension Study: final results. JAMA 1993;270:713-724.
28. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents with placebo. Circulation 1997;95:2007-2014.
29. Hollenberg NK, Epstein M, Basch RI, Merrill JP: "No man's land" of the renal vasculature. An arteriographic and hemodynamic assessment of the interlobar and arcuate arteries in essential and accelerated hypertension. Am J Med 1969;47:845-854.
30. London GM, Safar ME, Sassard JE, Levenson JA, Simon AC: Renal and systemic hemodynamics in sustained essential hypertension. Hypertension 1984;6:743-754.
31. Schmieder RE, Schächinger H, Messerli FH: Accelerated decline in renal perfusion with aging in essential hypertension. Hypertension. 1994;23:351-357.
32. de Leeuw PW, Gaillard CA, Birkenhäger WH: Renal hemodynamic patterns in essential hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. Vol 2. Second Edition. Raven Press, Ltd., New York, 1995, pp 1857-1867.
33. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155:1073-1080.
34. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-138.
35. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984;310:356-360.
36. Bauer JH: Diabetic nephropathy: can it be prevented? Are there renal protective antihypertensive drugs of choice? South Med J 1994;87:1043-1053.
37. Bauer JH, Brooks CS: The long-term effect of propranolol therapy on renal function. Am J Med 1979;66:405-410.
38. Folkow B: Physiological aspects of primary hypertension. Physiol Rev 1982;62:347-504.
39. Schiffrin EL, Deng LY, Larochelle P: Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994;23:83-91.
40. Schiffrin EL, Deng LY, Larochelle P: Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor: comparison with effects of a β-blocker. Am J Hypertens 1995;8:229-236.
41. Skarfors ET, Lithell HO, Selinus I, Åberg H: Do anti-hypertensive drugs precipitate diabetes in predisposed men? Br Med J 1989;298:1147-1152.
42. Bengtsson C, Blohmé G, Lapidus L, Lissner L, Lundgren H: Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: a 12-year prospective population study of women in Gothenburg, Sweden. J Intern Med 1992;231:583-588.
43. Pollare T, Lithell H, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989;298:1152-1157.
44. Lithell H, Pollare T, Vessby B: Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992;1:92-101.
45. Weidmann P, Ferrier C, Saxenhofer H, Uehlinger DE, Trost BN: Serum lipoproteins during treatment with antihypertensive drugs. Drugs 1988;35(suppl 6):118-134.
46. Grimm RH Jr: Antihypertensive therapy: taking lipids into consideration. Am Heart J 1991;122:910-918.
47. Roberts WC: Recent studies on the effects of beta blockers on blood lipid levels. Am Heart J 1989;117:709-714.
48. van Brummelen P, Buhler FR, Kiowski W, Amann FW: Age-related decrease in cardiac and peripheral vascular responsiveness to isoprenaline: studies in normal subjects. Clin Sci 1981;60:571-577.
49. Kasiske RL, Ma JZ, Kalil RSN, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995;122:133-141.
50. Lakatta EG, Gerstenblith G, Angell CS, Shock NW, Weisfeldt ML: Diminished inotropic response of aged myocardium to catecholamines. Circ Res 1975;36:262-269.
51. Guarnieri T, Filburn CR, Zitnik G, Roth GS, Lakatta EG: Contractile and biochemical correlates of β-adrenergic stimulation of the aged heart. Am J Physiol 1980; 239: H501-H508.
52. Feldman RD, Limbird LE, Nadeau J, Robertson D, Wood AJ: Alterations in leukocyte β-receptor affinity with aging. A potential explanation for altered β-adrenergic sensitivity in the elderly. N Engl J Med 1984; 310:815-819.
53. Stratton JR, Cerqueira MD, Schwartz RS, Levy WC, Veith RC, Kahn SE, Abrass IB: Differences in cardiovascular responses to isoproterenol in relation to age and exercise training in healthy men. Circulation 1992; 86:504-512.
54. Vlachakis ND, Aledort L: Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol 1980;45:321-325.
55. Fleg JL, Schulman S, O'Connor F, Becker LC, Gerstenblith G, Clulow JF, Renlund DG, Lakatta EG: Effects of acute β-adrenergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exercise. Circulation 1994;90:2333-2341.